Worsening pharmacoresistance to antiseizure drugs is common with ongoing excitotoxic neuronal and systemic injury. Early initiation of anesthetic drugs in refractory status epilepticus (RSE) may halt these processes while allowing time for treatment targeting the cause of the seizures. Current guidelines support the use of anesthetic drugs as the third line pharmacologic therapy in generalized convulsive status epilepticus but do not clearly define the indications for these drugs in other types of status epilepticus. There is wide practice variation in choice of third line therapy for RSE, but there is overall consensus that anesthetics should be initiated earlier in generalized convulsive status epilepticus than in nonconvulsive forms.
| INTRODUCTION
Status epilepticus (SE) is a neurologic and medical emergency in which early recognition and initiation of treatment leads to better treatment response and better outcomes. Refractory SE (RSE) is defined as continued seizure activity despite two appropriately selected and dosed antiseizure drugs including a benzodiazepine. General anesthetics are widely used to treat RSE despite a lack of randomized studies defining choice of anesthetic agent, dose, and duration of treatment or comparing them with nonanesthetic treatments. 1 There is general consensus among experts on first and second line pharmacologic treatment of SE, but wide variation of opinion remains when it comes to third line treatment options. [2] [3] [4] Options include additional nonsedating antiseizure drugs not used for second line treatment (eg, valproic acid, fosphenytoin, levetiracetam, lacosamide, or phenobarbital) and initiation of a continuous intravenous anesthetic drug (CIVAD). Current guidelines support the use of anesthetic drugs as the third line pharmacologic therapy in generalized convulsive SE (GCSE) but differ in the strength of their recommendations. [5] [6] [7] The European Federation of Neurologic Societies guideline advises that anesthesia be postponed in favor of further nonanesthetizing antiseizure drugs in complex partial SE (now focal nonconvulsive SE [NCSE] with impaired consciousness) 5 but do not address the indications for anesthesia in focal and nonconvulsive forms.
| DEFINING THE QUESTION
Some seizures are not controlled by benzodiazepines and nonanesthetic antiseizure drugs alone. Uncontrolled GCSE has devastating systemic and neurologic consequences.
Uncontrolled NCSE can also lead to systemic complications and may result in permanent neurologic sequelae. Furthermore, anesthetics are very effective antiseizure drugs. Initiation of a CIVAD may avoid worsening pharmacoresistance to antiseizure drugs and limit both excitotoxic neuronal injury and systemic complications while allowing time for treatment targeting the cause of the seizures. Conversely, anesthetic use has been consistently associated with longer hospital lengths of stay, death, and worse functional outcomes, [8] [9] [10] and evidence supporting their use is limited. All CIVADs cause respiratory depression, which must be managed with endotracheal intubation for airway protection and mechanical ventilation. They all cause some degree of hypotension, which must be managed with vasopressors, involving their inherent risks. The exception is ketamine, which causes hypotension in some patients and hypertension in others. However, ketamine, although short acting, may cause prolonged sedation when used in high doses and results in tachyarrhythmias in 5% of patients. 11 With prolonged use of midazolam at the doses typically required for seizure control, patients develop tachyphylaxis to the drug, significant volume accumulation, and prolonged sedation due to drug accumulation, particularly in the setting of obesity or renal failure.
12
Propofol can cause the sometimes fatal propofol infusion syndrome (rapid development of metabolic acidosis, renal failure, and cardiovascular collapse), and therefore its use should be limited to doses < 5 mg/kg/h for no more than 3 days and avoided in younger patients. 12 When using intravenous barbiturates, a number of serious adverse effects can be expected, including more pronounced cardiovascular depression and hypotension, paralytic ileus, anasarca, and an increased risk of pneumonia due to a reduction of ciliary function. Less commonly, patients can develop hepatic or pancreatic toxicity, propylene glycol toxicity, lingual edema, or rash. 13 Barbiturate infusions also can be expected to result in prolonged sedation. The practice of initiating a CIVAD for RSE has been called into question following a series of studies associating their use with worse outcomes, [8] [9] [10] leading some to shift away from early anesthesia in favor of further trials of nonsedating intravenous (IV) antiseizure drugs. The major limitation of these studies was that they did not control for RSE, raising the question of whether early use of anesthetic drugs causes harm or whether their use is necessarily more common in patients already prone to have a poor outcome. 14 
| ILLUSTRATIVE CASE
A 37-year-old woman was found comatose with a left hemiplegia hours after discharge following resection of a right temporal lobe glioma. She had cardiogenic shock due to apical ballooning syndrome, acute lung injury due to a combination of aspiration and neurocardiogenic pulmonary edema, acute renal failure and rhabdomyolysis, and a mixed respiratory and metabolic acidosis. On examination, she was stuporous with a right hemispheric syndrome. Electroencephalogram (EEG) showed a generalized spike and wave pattern, which did not change after 8 mg IV lorazepam and 20 mg/kg phenytoin equivalents IV fosphenytoin. The patient was intubated, given 0.2 mg IV midazolam, and started on an infusion of midazolam at 0.5 mg/kg/h, which produced a burst suppression pattern with no electrographic seizures over a 24-hour period. The midazolam was weaned over 10 hours, during which right frontal lateralized periodic discharges emerged and persisted. During the 32-day hospital course, she was weaned off pressors, treated for aspiration pneumonia, and transitioned from continuous venovenous hemodialysis to intermittent hemodialysis. She underwent tracheostomy and percutaneous gastrostomy tube placement. Over time, her severe encephalopathy improved and at discharge she was able to follow very simple commands inconsistently. Did midazolam increase this patient's morbidity? The answer is a definitive no. Her ultimate hemiplegia and dialysis dependence were predetermined at presentation and resulted from the presumably GCSE which evolved into NCSE in coma (so-called subtle SE). The simple truth is that those who need anesthetic drugs have more refractory seizures than those who do not. Patients with RSE, potentially fatal SE etiologies, significant comorbidities, and increased SE severity scores are more likely to die, explaining the association identified in prior studies. A recent study retrospectively evaluating patients from a prospective multicenter SE registry examined the impact of anesthetic use on mortality and found no association after controlling for refractoriness. 15 Additional important findings of this study were the remarkable difference in the frequency of anesthetic drug use between
Key Points
• Current guidelines support the use of anesthetic drugs as the third line pharmacologic therapy in generalized convulsive status epilepticus • Mortality increases with progressive refractoriness of seizures, and return to functional baseline is less likely in refractory than in nonrefractory status epilepticus • Patient selection and limiting overall doses may be the keys to optimizing the use of anesthetic drugs in status epilepticus centers in the United States (25.4%) and Switzerland (9.75%) despite "relatively uniform treatment guidelines," and the demonstration of overall poor adherence to guidelines for first and second line treatments, particularly in the US centers. It has been hypothesized that this may result from more use of continuous EEG monitoring in the United States resulting in identification of more electrographic seizures or other patterns on the ictal-interictal continuum, and that NCSE in coma was more frequent in the US center supports this theory. Perhaps the question should not be "are anesthetics harming the patient," but rather (1) who benefits most from anesthetics, (2) in whom are they potentially introducing more harm than benefit, (3) can we limit their adverse effects (eg, with careful protocols), and (4) can we do a better job of limiting exposure (eg, are we overtreating EEG patterns of uncertain clinical significance during treatment or weaning)?
| INDICATIONS FOR ANESTHESIA
Mortality increases with progressive refractoriness, [16] [17] [18] [19] [20] [21] and return to functional baseline is less likely in RSE than in SE. 22 Death is typically due to either progression of the underlying disease, transition to palliative care, or systemic complications. [8] [9] [10] 14, 15, 17 Convulsive SE leads to irreversible neuronal injury and serious systemic sequelae including primarily cardiopulmonary, renal, and musculoskeletal complications. 12 Uncontrolled NCSE increases the risk of a number of systemic complications, typically less severe than those associated with GCSE, but the impact on the brain is less clear. Studies evaluating the effects of NCSE in humans are difficult to interpret, as it can be difficult to parse out injury resulting from nonconvulsive seizures from damage arising as a result of the underlying cause of SE. 23 Although few studies have directly measured cognitive consequences of NCSE, two studies in patients with epilepsy compared cognitive measures before and after an episode of NCSE and found no cognitive decline. 24, 25 Conversely, studies comparing patients with subarachnoid hemorrhage or traumatic brain injury with controls suggest at least an additive negative effect of NCSE or seizures on the initial brain injury. 26 Taken together, these factors argue for judicious use of CIVADs in NCSE and more aggressive use in GCSE, and for the most part current guidelines support this practice. Data are even more limited to guide the initiation of CIVADs in focal motor or focal NCSE (Table 1 ). The recommendations outlined in Table 1 are based on an assessment of the risks and benefits and available evidence as outlined above. Other important factors that may argue for avoidance of an anesthetic drug include multiorgan failure, severe dementia, metastatic cancer, and other progressive untreatable disorders.
| PRACTICALITIES
Prior to initiation of an anesthetic drug, patients should be endotracheally intubated and preparations made to treat the anticipated hypotension. Recommended bolus doses and infusion rates of the CIVADs are included in Table 2 . After initiation of a CIVAD, it is standard practice to target electrographic seizure control or burst suppression for 24-48 hours prior to a gradual withdrawal of the CIVAD. 6 Limited evidence suggests that EEG background is not predictive of outcomes. 16, 19, 27 The optimal duration of electrographic control prior to attempting an anesthetic wean, the optimal depth of background suppression, and the optimum speed of weaning are not known. Upon weaning anesthesia, seizures or other patterns on the ictal-interictal continuum may emerge. It is unclear which patterns truly require treatment, although most experts agree that recurrence of clear electrographic seizures should be treated. Options include using additional rapidly acting IV antiseizure drugs or returning to the prior dose of CIVAD that previously controlled the seizures. How long to wait between additional weaning attempts is completely unknown. A common practice is to gradually lengthen the duration between cycles, although the advisability of this practice is questionable. Perhaps we should move toward daily so-called sedation holidays even if it means allowing more electrographic seizures. This would limit the cumulative dose of anesthesia with likely limited risk. In between weaning attempts, efforts are focused on treating the underlying cause of RSE, titrating the levels of the nonanesthetic antiseizure drugs to therapeutic levels, and the daily details of medical care. Careful attention to the daily medical management of these patients is critical. The most common problems are accumulation of fluid, ileus, recurrent infections (predominantly pneumonia), and venous thromboembolism. These can sometimes be prevented with daily physical examinations focused on volume assessment, abdominal examination, lung auscultation, and skin/extremity examinations as well as preventive practices including mobilization to a socalled chair mode three times daily, use of a scheduled pharmacologic bowel regiment, and periodic screening venous duplex ultrasounds of the extremities. CIVAD infusions may be concentrated to avoid unnecessary volume administration.
T A B L E 1 Proposed indications for initiation of CIVADs
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| CONCLUSIONS
A number of questions remain unanswered. Do associations of CIVADs with mortality and functional outcome vary by SE type? What is the optimal EEG treatment target? How often should weaning be attempted and what electrographic patterns emerging out of anesthesia really need treating?
Priorities include (1) prevention of RSE development through improved adherence to treatment guidelines in the early stages of SE; (2) studies aimed at determining the optimal timing of initiation of CIVADs depending on type of SE, and (3) clarification of the optimal dosing, EEG treatment target, and weaning strategies. Patient selection and limiting overall doses may be the keys to optimizing the use of CIVADs. Death results from either transition to palliative care when treatment options have been exhausted, progression of underlying disease, or systemic complications. Careful prevention protocols are likely to reduce the number of deaths from systemic complications in the setting of CIVAD use.
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